Although early trials evaluating the efficacy of insulin showed promise, unfortunately, this result in a larger sample of AD patients indicated that intranasal insulin was insufficient to provide symptomatic or disease-modifying benefits. This evidence concerns the gene INS and Alzheimer disease.